OCC Orthocell

Orthocell Announces Collaboration with Johnson & Johnson Innovation

PERTH, Australia--(BUSINESS WIRE)--

Regenerative medicine company Orthocell Limited has today announced a research collaboration agreement with DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, for its Ortho-ATI® stem cell approach for the regeneration of degenerate tendons and ligaments. The collaboration was facilitated by Johnson & Johnson Innovation.

Ortho-ATI is a novel non-surgical approach to treat chronic treatment resistant tendon injuries that have a significant negative effect on patients’ activities of daily living.

A collaborative study is planned to commence in Q1 2017 and will be a multi-center trial conducted with one of Australia’s leading orthopaedic surgeons. The trial will be led by prominent Orthopaedic Surgeon, Professor Allan Wang from the University of Western Australia and current President of the 'Shoulder and Elbow Society of Australia' (SESA).

Managing Director Mr. Paul Anderson commented, “This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology.”

In studies conducted by Orthocell to date, Ortho-ATI has been shown to be a cost effective and durable non-surgical solution for difficult to treat tendon injuries. Ortho-ATI is available in Australia and New Zealand for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs and have ongoing symptoms.

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed Autologous cell therapies, Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

EN
12/01/2017

Underlying

OCCOrthocell

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orthocell

Free Trial
OCC ORTHOCELL

Orthocell Ltd: 2 directors

Two Directors at Orthocell Ltd sold 1,570,618 shares at 0.479AUD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

09/24/21 September 24, 2021 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Positive Pre-Clinical Results Using CelGro® in Anterior Cruciate Liga...

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC) (“Orthocell” or the “Company”) is pleased to announce positive pre-clinical results using CelGro® collagen rope for Anterior Cruciate Ligament (ACL) reconstruction. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005104/en/ Figure 1 - An illustration depicting a ruptured ACL (Graphic: Business Wire) Orthocell Managing Director Paul Anderson said: “We are extremely exci...

February 5, 2018 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Secures New Patent for Suture-Less Repair of Soft Tissue

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a further Australian patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled “Suture-less repair of soft tissue” provides additional important intellectual property to protect the CelGro® product platform. Orthocell Managing Director Paul Anderson said: “This is an important addition to ou...

January 18, 2018 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Granted European Tendon Regeneration Patent

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled ‘Culture medium, culturing method and use of tenocytes’ protecting the method of manufacturing tendon regeneration cells (Tenocytes) to form the Autologous Tenocyte Implantation (Ortho-ATI®) product. The patent expires in 2027 and provides additional important intellectual property (IP) to protect Orthocell’s tendon repair ap...

December 15, 2017 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Commences Treatment of Its 1,000th Patient

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce that it has commenced treatment of its 1,000th patient, in its TGA licensed manufacturing facility using the Company’s proprietary tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia. This marks a significant milestone in the Company’s history as it continues to clinically validate its market leading regenerative medicine...

December 7, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch